Literature DB >> 28800870

Recent advances in HER2 positive breast cancer epigenetics: Susceptibility and therapeutic strategies.

Heena Singla1, Abhilash Ludhiadch1, Raman Preet Kaur1, Harish Chander1, Vinod Kumar2, Anjana Munshi3.   

Abstract

HER2 amplification/overexpression accounts for aggressive clinical features of HER2 positive breast cancer. Epigenetic changes including DNA methylation, histone modifications and ncRNAs/miRNAs are associated with regulation of DNA chromatin and specifically, gene transcription. Hence, these produce eminent effects upon proto-oncogenes, tumor-suppressors and key cancer-regulatory signaling pathways. Understanding of epigenomic regulation of HER2 overexpression and signaling may help uncover the unmatchable physiology of HER2 gene/protein. Moreover, this may also aid in resolving the major issue of resistance-development towards HER2 targeted agents (trastuzumab and lapatinib), since epigenetic alterations are important therapeutic markers and modulate the response towards HER2 targeted therapy. Therefore, in this review the information regarding various epigenetic markers implicated in HER2 positive breast cancer susceptibility and therapeutic-strategies has been compiled.
Copyright © 2017 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  DNA methylation; HER2 positive breast cancer; Histone modifications; Susceptibility; Therapy; miRNA; ncRNA

Mesh：

Substances：

Year:  2017        PMID： 28800870     DOI： 10.1016/j.ejmech.2017.07.075

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN： 0223-5234            Impact factor:   6.514


  8 in total

1.  IFI16-dependent STING signaling is a crucial regulator of anti-HER2 immune response in HER2+ breast cancer.

Authors:  Li-Teng Ong; Wee Chyan Lee; Shijun Ma; Gokce Oguz; Zhitong Niu; Yi Bao; Mubaraka Yusuf; Puay Leng Lee; Jian Yuan Goh; Panpan Wang; Kylie Su Mei Yong; Qingfeng Chen; Wenyu Wang; Adaikalavan Ramasamy; Dave S B Hoon; Henrik J Ditzel; Ern Yu Tan; Soo Chin Lee; Qiang Yu
Journal:  Proc Natl Acad Sci U S A       Date:  2022-07-25       Impact factor: 12.779

Review 2.  Novel applications of molecular imaging to guide breast cancer therapy.

Authors:  Christine E Edmonds; Sophia R O'Brien; David A Mankoff; Austin R Pantel
Journal:  Cancer Imaging       Date:  2022-06-21       Impact factor: 5.605

Review 3.  Targeting bromodomain and extraterminal proteins in breast cancer.

Authors:  Jennifer M Sahni; Ruth A Keri
Journal:  Pharmacol Res       Date:  2017-11-16       Impact factor: 7.658

4.  Involvement of miR-770-5p in trastuzumab response in HER2 positive breast cancer cells.

Authors:  Senem Noyan; Hakan Gurdal; Bala Gur Dedeoglu
Journal:  PLoS One       Date:  2019-04-22       Impact factor: 3.240

5.  Contribution of synergism between PHF8 and HER2 signalling to breast cancer development and drug resistance.

Authors:  Qi Liu; Nicholas C Borcherding; Peng Shao; Peterson K Maina; Weizhou Zhang; Hank H Qi
Journal:  EBioMedicine       Date:  2020-01-07       Impact factor: 8.143

Review 6.  Epigenetics in Inflammatory Breast Cancer: Biological Features and Therapeutic Perspectives.

Authors:  Flavia Lima Costa Faldoni; Cláudia Aparecida Rainho; Silvia Regina Rogatto
Journal:  Cells       Date:  2020-05-08       Impact factor: 6.600

7.  Analysis of Copy-Number Variations and Feline Mammary Carcinoma Survival.

Authors:  Hugo Murua Escobar; Ingo Nolte; José Luis Granados-Soler; Kirsten Bornemann-Kolatzki; Julia Beck; Bertram Brenig; Ekkehard Schütz; Daniela Betz; Johannes Junginger; Marion Hewicker-Trautwein
Journal:  Sci Rep       Date:  2020-01-22       Impact factor: 4.379

8.  Construction of differentially expressed Her-2 related lncRNA-mRNA-miRNA ceRNA network in Her-2 positive breast cancer.

Authors:  Xiaochen Jia; Wenjing Meng; Lu Zhang; Yongsheng Jia; Yehui Shi; Zhongsheng Tong
Journal:  Transl Cancer Res       Date:  2020-04       Impact factor: 1.241
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.